Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

William H. Rastetter net worth and biography

William Rastetter Biography and Net Worth

Director of Neurocrine Biosciences

William H. Rastetter, Ph.D., has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. Currently, he serves as the Chairman of the Board of Directors for Fate Therapeutics, a publicly traded company focused on cellular therapies, as well as for Daré Bioscience, Inc. (previously known as Cerulean Pharma Inc.), a publicly traded company focused on women’s healthcare. Dr. Rastetter also serves on the Board of Directors for Regulus Therapeutics Inc., a publicly traded company focused on RNA-based therapeutics. Dr. Rastetter previously served on the board of Grail, Inc., a private company developing deep sequencing approaches for disease diagnosis, with an initial focus on the early diagnosis of cancer. Dr. Rastetter serves as an advisor to Illumina Ventures, and is the Chairman of San Diego Squared, a nonprofit focused on STEM awareness and education for students in underserved communities. Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013 and was Executive Chairman of Biogen Idec, Inc. from 2003 to 2005. Earlier, he served as Chairman and Chief Executive Officer of IDEC Pharmaceuticals Corporation until its merger with Biogen in 2003; he joined IDEC Corporation as its Chief Executive Officer at the company’s founding in 1986. From 1984 to 1986, Dr. Rastetter was Director of Corporate Ventures at Genentech, where from 1982 to 1984 he held scientific positions. He held a series of faculty positions including Associate Professor at the Massachusetts Institute of Technology (“MIT”) from 1975 to 1982. Dr. Rastetter has a B.S. degree in Chemistry from MIT and received M.A. and doctorate degrees in Chemistry from Harvard University.

What is William H. Rastetter's net worth?: The estimated net worth of William H. Rastetter is at least $6.83 million as of January 2nd, 2024. Dr. Rastetter owns 51,741 shares of Neurocrine Biosciences stock worth more than $6,829,812 as of April 19th. This net worth estimate does not reflect any other assets that Dr. Rastetter may own. Learn More about William H. Rastetter's net worth.
How do I contact William H. Rastetter?: The corporate mailing address for Dr. Rastetter and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on William H. Rastetter's contact information.
Has William H. Rastetter been buying or selling shares of Neurocrine Biosciences?: William H. Rastetter has not been actively trading shares of Neurocrine Biosciences during the last quarter. Most recently, William H. Rastetter sold 11,044 shares of the business's stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $131.47, for a transaction totalling $1,451,954.68. Following the completion of the sale, the director now directly owns 51,741 shares of the company's stock, valued at $6,802,389.27. Learn More on William H. Rastetter's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 48 times. They sold a total of 520,295 shares worth more than $67,323,483.36. The most recent insider tranaction occured on April, 15th when insider Eric Benevich sold 19,818 shares worth more than $2,642,928.48. Insiders at Neurocrine Biosciences own 4.4% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 4/15/2024.

William H. Rastetter Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/2/2024	Sell	11,044	$131.47	$1,451,954.68	51,741
5/1/2023	Sell	4,300	$101.43	$436,149.00	42,785
4/21/2023	Sell	6,034	$105.04	$633,811.36	39,460
4/19/2023	Sell	903	$105.00	$94,815.00	34,729
4/1/2022	Sell	10,728	$94.93	$1,018,409.04	34,022
1/24/2018	Sell	9,500	$90.00	$855,000.00	34,250
2/1/2017	Sell	10,750	$42.28	$454,510.00	25,000

William H. Rastetter Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $132.00

$130.13

$133.65

50 Day Range

MA: $136.15

$130.40

$143.74

2 Week Range

Now: $132.00

$89.04

$148.37

Volume

556,052 shs

Average Volume

843,646 shs

Market Capitalization

$13.14 billion

P/E Ratio

54.55

Dividend Yield

N/A

Beta

0.25

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad